Received Jan 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 1 | — | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 2 | — | — |
No symptoms reported; an adult patient was administered a pediatric dose; an adult patient was administered a pediatric dose; This spontaneous report was received from a other health professional and refers to a 22-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 02-Dec-2025, the patient's lab showed no immunity for Hepatitis B. Then, on that day, the patient received the first dose of hepatitis B vaccine (recombinant) (RECOMBIVAX HB) pediatric dose (route, lot # and expiration date were not reported) (vaccine underdose). On 05-Jan-2026, the patient received the second dose with hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) pediatric doses (route, lot # and expiration date were not reported) for prophylaxis (vaccine underdose). No symptoms were reported.
Test Date: 20251202; Test Name: lab; Result Unstructured Data: no immunity for Hepatitis B